Oncology · Colorectal CancerTrial Updateclinicalmid-term

Comparative Study of Raltitrexed and Oxaliplatin in Metastatic Colorectal Cancer

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Pfizer146 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/25/2026, 6:01:38 AM

Assessment confidence: 68% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

This trial is significant as it explores a potential alternative to 5FU in treating metastatic colorectal cancer, which could reshape treatment protocols. The outcomes may influence market dynamics and competitive positioning for oncology products. Regulatory context from FDA (Verified Clinical Benefit | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 16 ranked evidence items (8 high-relevance).

Strategic Assessment

If successful, this study may position raltitrexed as a viable alternative to 5FU, influencing treatment protocols and market dynamics. The strongest clinical anchor is Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer (ClinicalTrials.gov), sub-indication match (colorectal cancer); entity match (pfizer). In colorectal cancer, 4 regulatory and 0 competitive items passed relevance filtering for Pfizer.

Competitive Pressure

The most relevant competitive pressure comes from This trial could provide insights into the efficacy and safety of raltitrexed in combination with oxaliplatin, potentially impacting treatment standards in colorectal cancer..

Regulatory Outlook

Regulatory risk is concentrated around Verified Clinical Benefit | Cancer Accelerated Approvals (FDA). Sponsor/company relevance (Pfizer). Relevant agencies in corpus: FDA, MHRA. Successful trial outcomes could lead to new treatment guidelines and potential regulatory approvals for raltitrexed, altering the landscape for colorectal cancer therapies.

Key Risks

Elevated medium regulatory exposure for Pfizer could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If raltitrexed proves effective, it could capture market share from 5FU, impacting revenue streams for companies involved in colorectal cancer therapies.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
If successful, this study may position raltitrexed as a viable alternative to 5FU, influencing treatment protocols and market dynamics.

What Would Change This Assessment

This becomes more urgent if Monitor the outcomes related to objective response rate, progression-free survival, and overall survival as the trial progresses.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Verified Clinical Benefit | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Other | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer); Entity match (pfizer)
FDA document
View source
Study Evaluating Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Pfizer); Patient population match (metastatic)
FDA document
View source
A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Pfizer); Patient population match (metastatic)
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

No evidence in this category.

Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Entity match (oxaliplatin)
FDA document
View source
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
Association of Intraoperative Fluid Exposure with Time to First Flatus after Laparoscopic Radical Resection for Colorectal Cancer: A Retrospective Cohort Study.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
Early prediction of minimal residual disease in colorectal cancer via SEPTIN9 methylation status in circulating tumor DNA.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Pfizer
Raltitrexed
Oxaliplatin

Commercial impact

medium

If raltitrexed proves effective, it could capture market share from 5FU, impacting revenue streams for companies involved in colorectal cancer therapies.

Regulatory impact